Patrick Ashe
No más puestos en curso
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Christopher Paul Blackwell | M | 62 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 18 años |
Joe Carthy | M | - |
University College Dublin
| 40 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
David Kelly | M | 63 |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL.
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 2 años |
Arnold Lippa | M | 77 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 11 años |
Virinder Nohria | M | 70 |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | - |
John Devane | M | - |
Athpharma Ltd.
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL.
University College Dublin
| 8 años |
Sian Bigora | M | 63 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 3 años |
Mary Martin | M | - |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL.
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 8 años |
Barbara Duncan | F | 59 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 8 años |
John Kelleher | M | - |
University College Dublin
| 9 años |
Kieran Gartlan | M | - |
University College Dublin
| 5 años |
Phil Skolnick | M | 77 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 8 años |
David Young | M | 71 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 3 años |
Liam Michael FitzGerald | M | 58 |
University College Dublin
| 5 años |
Bala Venkataraman | M | 57 |
HZNP USA LLC
HZNP USA LLC Pharmaceuticals: MajorHealth Technology HZNP USA LLC acquires, develops, markets and distributes specialty pharmaceutical products. The firm offers Actimmune, which is a bioengineered form of interferon gamma-1b, a protein that acts as a biologic response modifier through stimulation of the human immune system. Its Actimmune product is used for reducing the frequency and severity of serious infections related to chronic granulomatous diseases, and for delaying time to disease progression in patients with severe malignant osteopetrosis. The company was founded in 2011 by Balaji K. Venkataraman and Virinder Nohria and is headquartered in Lake Forest, FL. | - |
Cyril McGuire | M | 64 |
University College Dublin
| 4 años |
Fintan Drury | M | 65 |
University College Dublin
| 1 años |
Brian T. Hayden | M | 76 |
University College Dublin
| 2 años |
Pauline Mary Walsh | F | 57 |
University College Dublin
| 4 años |
Fergal McGovern | M | - |
University College Dublin
| 4 años |
Jarlath McEntee | M | - |
University College Dublin
| 4 años |
Khalid Jasim | M | - |
University College Dublin
| 3 años |
Brendan Phelan | M | - |
University College Dublin
| 4 años |
David Anthony Cooke | M | - |
University College Dublin
| 4 años |
Stephen Keeney | M | - |
University College Dublin
| 4 años |
Dermot Barry | M | - |
University College Dublin
| 4 años |
Scott Myers | M | 57 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 2 años |
Seamus MacKenna | M | - |
University College Dublin
| 4 años |
Oengus Ramsay | M | - |
University College Dublin
| 4 años |
Niall O'Donnellan | M | - |
DCU Business School
| - |
David Macdara Moloney | M | 62 |
University College Dublin
| 4 años |
Camillus Glover | M | - |
University College Dublin
| 4 años |
Peter Smyth | M | - |
University College Dublin
| 4 años |
Patrick Kelly | M | - |
University College Dublin
| 4 años |
Paul Stenson | M | 62 |
University College Dublin
| 3 años |
Adrian Waters | M | 60 |
University College Dublin
| 4 años |
Denis O'Flynn | M | - |
University College Dublin
| 4 años |
Wendy Guy | F | 59 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 4 años |
Philipp Graf von Matuschka | M | - |
University College Dublin
| 5 años |
Mary P Corcoran | F | - |
University College Dublin
| 4 años |
Daniel S. van Riper | M | 83 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 6 años |
Ciaran Hynes | M | - |
University College Dublin
| 3 años |
Cian Hughes | M | 58 |
University College Dublin
| 4 años |
Gilmore O’Neill | M | 59 |
University College Dublin
| 4 años |
Ronan Lambe | M | 84 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 6 años |
John O'Connor | M | - |
University College Dublin
| 3 años |
Stephen Drumm | M | - |
University College Dublin
| 4 años |
Martin Leahy | M | - |
University College Dublin
| 4 años |
Michael Kennedy | M | - |
University College Dublin
| 4 años |
Ali Hewson | F | 63 |
University College Dublin
| 4 años |
Jeanne Bolger | M | - |
University College Dublin
| 6 años |
David Gallagher | M | - |
University College Dublin
| 4 años |
Maurice Benedict Horan | M | 68 |
University College Dublin
| 2 años |
Gerard Clarke | M | - |
University College Dublin
| 4 años |
Eoin Howlett | M | - |
University College Dublin
| 4 años |
Stuart Apfel | M | 63 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 2 años |
Johanna Carmel Egan | M | - |
University College Dublin
| 3 años |
Eileen Fitzpatrick | M | - |
University College Dublin
| 3 años |
Patrick John Carmody | M | - |
University College Dublin
| 4 años |
Ian Sparling | M | 58 |
University College Dublin
| 4 años |
Robert P. Hadden | M | 61 |
University College Dublin
| 4 años |
Alan Merriman | M | - |
University College Dublin
| 4 años |
John O'Sullivan | M | - |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 8 años |
Adrian Jones | M | 59 |
University College Dublin
| 4 años |
Tony Murphy | M | - |
University College Dublin
| 4 años |
Joseph Zakrzewski | M | 60 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 1 años |
Seán Melly | M | - |
University College Dublin
| 1 años |
Seamus Lynch | M | 55 |
University College Dublin
| 4 años |
Richard Duggan | M | - |
University College Dublin
| 4 años |
Oonagh McCutcheon | F | - |
University College Dublin
| 4 años |
Dennis Podlesak | M | 66 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Siobhán Talbot | F | 60 |
University College Dublin
| 4 años |
Theresa A. Bischoff | F | 69 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Warren C. Stern | M | 79 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
Ronan Reid | M | 50 |
University College Dublin
| 4 años |
Jonathan Silverstein | M | 57 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
J. Robert Horton | M | 88 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | - |
James Francis Kenny | M | 80 |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 8 años |
Abdel-Fattah Abdel Hamid Mohammad Al-Nsour | M | 71 |
University College Dublin
| 4 años |
Aidan Dillon | M | - |
University College Dublin
| 4 años |
Peter Sandys | M | - |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 8 años |
Seamus O'Hara | M | - |
University College Dublin
| 4 años |
James O'Riordan | M | - |
University College Dublin
| 4 años |
Amir Shojaei | M | - |
AGI Therapeutics Plc
AGI Therapeutics Plc Pharmaceuticals: MajorHealth Technology AGI Therapeutics Plc provides pharmaceutical services. The firm engages in development and commercialization of differentiated drug products to treat unmet medical needs, including conditions which qualify for orphan drug status. The company was founded by John Devane and Patrick Ashe in 2003 and is headquartered in Dublin, Ireland. | 2 años |
O'Keeffe Edmund | M | 57 |
University College Dublin
| - |
Michael Reilly | M | - |
University College Dublin
| 4 años |
Leslie Hudson | M | 76 |
DOV Pharmaceutical, Inc.
DOV Pharmaceutical, Inc. Miscellaneous Commercial ServicesCommercial Services DOV Pharmaceutical, Inc. discovers and develops novel drugs. It focuses on the development of novel product candidates for disorders of the central nervous system, or CNS. It have drug development programs that are at the preclinical, Phase I and Phase II clinical stages, including DOV 21,947 (in a Phase II clinical trial for depression), DOV 102,677 (which has completed a Phase I clinical trial) and a preclinical discovery program in reuptake inhibitors and GABA modulators. The company was founded by Arnold S. Lippa in May, 1995 and is headquartered in Somerset, NJ. | 1 años |
Ciaran Murray | M | 61 |
University College Dublin
| 4 años |
John Coleman O'Donohue | M | 60 |
University College Dublin
| 4 años |
Thomas Murray | M | - |
University College Dublin
| 4 años |
Karl Keegan | M | 57 |
University College Dublin
| 4 años |
James O'Shaughnessy | M | 61 |
University College Dublin
| 1 años |
Kieran Murphy | M | 61 |
University College Dublin
| 4 años |
Rory John Williams | M | 59 |
University College Dublin
| 3 años |
Martin McAdam | M | 62 |
University College Dublin
| 4 años |
Alexander Davern | M | 57 |
University College Dublin
| 4 años |
Joseph Concannon | M | - |
University College Dublin
| 4 años |
Mick Sweeney | M | - |
University College Dublin
| 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Irlanda | 83 | 84.69% |
Estados Unidos | 18 | 18.37% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Patrick Ashe
- Red Personal